Table 5.
Anticancer activity of compounds (4a–4r).
| Compound | Concentration (μg/mL) | OD at 492 nm | % of cell lysis | IC50 (μg/mL) |
|---|---|---|---|---|
| 4b | 10 | 0.799 | 75% | <10 μG |
| 4b | 20 | 0.885 | >75% | |
| 4b | 30 | 1.559 | 100% | |
| 4e | 10 | 0.701 | >50% | <10 μG |
| 4e | 20 | 0.915 | 75% | |
| 4e | 30 | 1.010 | >75% | |
| 4h | 10 | 0.453 | <50% | 20 μG |
| 4h | 20 | 0.550 | 50% | |
| 4h | 30 | 0.799 | 75% | |
| 4k | 10 | 1.333 | 100% | Very <10 μG |
| 4k | 20 | 1.548 | 100% | |
| 4k | 30 | 1.873 | 100% | |
| 4n | 10 | 1.143 | >75% | <10 μG |
| 4n | 20 | 1.734 | 100% | |
| 4n | 30 | 1.822 | 100% | |
| 4q | 10 | 0.956 | 100% | Very <10 μG |
| 4q | 20 | 1.392 | 100% | |
| 4q | 30 | 1.752 | 100% | |
| 4r | 10 | 0.377 | No lysis | 20 μG |
| 4r | 20 | 0.606 | 50% | |
| 4r | 30 | 0.700 | >50% | |
| Control | — | 0.349 | No lysis |
Cell line-MDA-MB-human adenocarcinoma, mammary gland.